CoChat

Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective

Open access
Harris, Stewart, Cimino, Sal, Nguyen, Yen, Szafranski, Kirk, Poon, Yeesha · 2025 · Diabetes Therapy

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

For people living with diabetes, effective glucose monitoring is a key component in diabetes care, helping to reduce disease burden, complications, and healthcare utilization. Sensor-based glucose monitoring systems, which can provide more comprehensive information about glucose levels than capillary-based self-monitoring of blood glucose (SMBG), are becoming established among people living with diabetes. The objective of this study was to assess the cost-effectiveness of glucose monitoring with FreeStyle Libre systems, compared with SMBG, from the perspective of a Canadian private payer. The analysis used the validated, person-level microsimulation model DEDUCE (Determination of Diabetes Utilities, Costs, and Effects). Analyses were conducted separately for populations of people with type 1 and type 2 diabetes mellitus (T1DM; T2DM), with time horizons of 40 and 25 years, respectively. T2DM treatment was assumed to be 84% non-insulin, 10% basal insulin, and 6% multiple daily injections of insulin. The effect of FreeStyle Libre was modeled as reductions versus SMBG in glycated hemoglobin level (T1DM, − 0.42%; insulin-treated T2DM, − 0.59%; non-insulin-treated T2DM, − 0.3%) and in acute diabetic events (hypoglycemia and diabetic ketoacidosis). Costs (in 2023 Canadian dollars (Can$)) and utilities were discounted at 1.5%. Outcomes were assessed as costs and quality-adjusted life years (QALYs). In both populations, FreeStyle Libre was dominant to SMBG, providing more QALYs at a lower cost (T1DM: + 1.25 QALYs, − Can$32,287 costs; T2DM: + 0.48 QALYs, − Can$8091 costs). Reductions were seen in the cumulative incidence of all complications (except blindness in the T1DM analysis). FreeStyle Libre was dominant to SMBG in all scenarios tested. Probabilistic sensitivity analysis showed that FreeStyle Libre had a 100% probability of being dominant to SMBG for T1DM and a 91% probability of being dominant for T2DM. This economic analysis shows that, from a Canadian private payer perspective, FreeStyle Libre is cost-effective compared with SMBG for all people living with diabetes. Glucose monitoring is important for people living with diabetes. Effective glucose monitoring can reduce the risk of hypoglycemia (low blood sugar), diabetic ketoacidosis (a potentially life-threatening complication which occurs when the body has low insulin and high blood sugar levels), and long-term complications. This can be done using finger sticks and test strips or sensor-based devices such as the FreeStyle Libre systems. In this study, we modeled the effect of FreeStyle Libre use in persons living with type 1 or type 2 diabetes mellitus in Canada using the DEDUCE economic model. In both analyses, FreeStyle Libre use was predicted to lead to better outcomes (measured as quality-adjusted life years—a measure of health which combines life expectancy with quality of life) for people living with diabetes while reducing costs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-024-01677-5

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Probabilistic sensitivity analysis scatterplots. Costs are in 2023 Canadian dollars. QALY quality-adjusted life year, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
Fig. 1 Probabilistic sensitivity analysis scatterplots. Costs are in 2023 Canadian dollars. QALY quality-adjusted life year, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitusCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 17

Metadata

Authors
Harris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y.
Affiliations
  • Western University (CA)
  • EVERSANA (Canada) (CA)
  • Abbott (Canada) (CA)
Corresponding author
Poon, Yeesha
Venue
Diabetes Therapy
Published
2024-12-17
Volume
16
Issue
2
Pages
169-186
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4405458940
Cited by
12
References
67
Citations by year
2026: 7 · 2025: 5
FWCI
3.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
FreeStyle Libre, continuous glucose monitoring, diabetes self-management, type 1 diabetes, type 2 diabetes, self-monitoring of blood glucose, cost-effectiveness, HbA1c, hypoglycemia, diabetic ketoacidosis, quality-adjusted life years, Canadian healthcare costs, diabetes complications, insulin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective. https://app.cochat.ai/papers/10.1007/s13300-024-01677-5
The paper
Harris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y. (2025). Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01677-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.